Pitavastatin – pharmacological profile from early phase studies (Q37824750)

23 August 2017

1 reference

title

Pitavastatin - pharmacological profile from early phase studies (English)

1 reference

23 August 2017

Pitavastatin – pharmacological profile from early phase studies (English)

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(10)71063-1

21 November 2024

1 reference

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21193152

21 November 2024

publication date

1 December 2010

1 reference

23 August 2017

December 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21193152

full work available at URL

21 November 2024

https://api.elsevier.com/content/article/PII:S1567568810710631?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(10)71063-1

https://api.elsevier.com/content/article/PII:S1567568810710631?httpAccept=text/plain

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(10)71063-1

Atherosclerosis. Supplements

21 November 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

3-7

1 reference

Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

1 reference

7 January 2021

Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis pr

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-dens

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Pitavastatin – results from phase III & IV

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2810%2971063-1

7 January 2021

Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(10)71063-1

Pitavastatin. Itavastatin, Nisvastatin, Nk 104, Nks 104, P 872441

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(10)71063-1

Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/S1567-5688(10)71063-1

21 November 2024

Identifiers

1 reference

23 August 2017

1 reference